基本數據
| CIK | 1621221 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Artelo Biosciences, Inc.
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2026 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 27, 2026 |
AT THE MARKET OFFERING AGREEMENT EXHIBIT 10.1 AT THE MARKET OFFERING AGREEMENT May 26, 2026 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Artelo Biosciences, Inc., a corporation organized under the laws of Nevada (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agreem |
|
| May 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| May 26, 2026 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-295537 PROSPECTUS SUPPLEMENT (To Prospectus dated May 19, 2026) $6,530,000 Common Stock This prospectus supplement relates to the issuance and sale of shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $6,530,000, from time to time solely through H.C. Wainwright & Co., LLC, as exclusive sales age |
|
| May 18, 2026 |
The date of this prospectus supplement is May 18, 2026. Filed Pursuant to Rule 424(b)(5) Registration No. 333-273153 PROSPECTUS SUPPLEMENT (To Prospectus Supplements dated July 18, 2025, September 4, 2025, and September 30, 2025 to Prospectus dated July 14, 2023) This prospectus supplement amends and supplements the information in the prospectus supplement, dated July 18, 2025, as supplemented by prospectus supplements dated September 4, 2025 and Septe |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 14, 2026 |
BYLAWS ARTELO BIOSCIENCES, INC. SECTION 1 SHAREHOLDERS' AND SHAREHOLDERS' MEETINGS EXHIBIT 3.2 BYLAWS OF ARTELO BIOSCIENCES, INC. SECTION 1 SHAREHOLDERS' AND SHAREHOLDERS' MEETINGS 1.1 Annual Meeting. The annual meeting of the shareholders of Artelo Biosciences, Inc. (the "Corporation") for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at the principal office of the corporation, or at some |
|
| May 14, 2026 |
As filed with the Securities and Exchange Commission on May 14, 2026 As filed with the Securities and Exchange Commission on May 14, 2026 Registration No. |
|
| May 14, 2026 |
EXHIBIT 3.1 |
|
| May 14, 2026 |
ARTELO BIOSCIENCES, INC. Dated as of ________________ EXHIBIT 4.3 ARTELO BIOSCIENCES, INC. INDENTURE Dated as of [] Trustee 1 TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE. 6 Section 1.1 Definitions. 6 Section 1.2 Incorporation by Reference of Trust Indenture Act. 8 Section 1.3 Rules of Construction. 8 ARTICLE II THE SECURITIES. 9 Section 2.1 Issuable in Series. 9 Section 2.2 Establishment of Terms of Series of Securities. 9 |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2026 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO B |
|
| May 4, 2026 |
As filed with the Securities and Exchange Commission on May 4, 2026 As filed with the Securities and Exchange Commission on May 4, 2026 Registration No. |
|
| May 4, 2026 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Artelo Biosciences, Inc. |
|
| April 16, 2026 |
Artelo Biosciences, Inc. UP TO 9,820,294 SHARES OF COMMON STOCK Filed Pursuant to Rule 424(b)(3) Registration No. 333-294912 PROSPECTUS Artelo Biosciences, Inc. UP TO 9,820,294 SHARES OF COMMON STOCK This prospectus relates to the offer and resale from time to time of: · 81,000 shares of common stock, par value $0.001 per share (the “Common Stock”), of Artelo Biosciences, Inc., a Nevada corporation (the “Company”), held by Intracoastal Capital LLC, a Delaware |
|
| April 13, 2026 |
April 13, 2026 Gregory D. Gorgas Chief Executive Officer Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 Re: Artelo Biosciences, Inc. Registration Statement on Form S-1 Filed April 07, 2026 File No. 333-294912 Dear Gregory D. Gorgas: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regar |
|
| April 13, 2026 |
Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 April 13, 2026 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC. 20549 Attn: Doris Stacey Gama Re: Artelo Biosciences, Inc. Registration Statement on Form S-1 (File No. 333-294912) Ladies and Gentlemen, Pursuant to Rule 461 under the Securities Act of 1933, as amended, Artelo Biosciences, Inc. he |
|
| April 7, 2026 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Artelo Biosciences, Inc. |
|
| April 7, 2026 |
EXHIBIT 99.1 Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements Nasdaq confirms Company has regained compliance with Listing Rules 5550(b)(1) and 5620(a) SOLANA BEACH, Calif., April 7, 2026 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop treatments for people living wit |
|
| April 7, 2026 |
As filed with the Securities and Exchange Commission on April 7, 2026 As filed with the Securities and Exchange Commission on April 7, 2026 Registration No. |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2026 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission File |
|
| March 30, 2026 |
EXHIBIT 10.2 EXHIBIT A REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 27, 2026, between Artelo Biosciences, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securitie |
|
| March 30, 2026 |
PREFUNDED COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2026 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission File |
|
| March 30, 2026 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 30, 2026 |
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules EXHIBIT 99.1 Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules SOLANA BEACH, CA – March 27, 2026 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,188,407 shares of common stock (or pre-funded warrant in lieu thereof) and warrants |
|
| March 30, 2026 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 27, 2026, between Artelo Biosciences, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| March 30, 2026 |
EXHIBIT 99.2 Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules SOLANA BEACH, CA – March 30, 2026 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced the closing of its previously announced private placement of 3,188,407 shares of common stock (or pre-funded warrant in lieu thereof) and warrants to purchase up to 6 |
|
| March 30, 2026 |
COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 27, 2026 |
Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 March 27, 2026 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC. 20549 Attn: Doris Stacey Gama Re: Artelo Biosciences, Inc. Request for Withdrawal Registration Statement on Form S-1 (File No. 333-294506) Ladies and Gentlemen, Pursuant to Rule 477 of the Securities Act of 1933, as amended (“Securi |
|
| March 26, 2026 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 20, 2026, by and between Artelo Biosciences, Inc., a Nevada corporation, with headquarters located at 505 Lomas Santa Fe, Suite 160, Solana Beach, CA 92075 (the “Company”), and LABRYS FUND II, L.P., a Delaware limited partnership, with its address at 145 Tremont Street, Suite 201-1408 |
|
| March 26, 2026 |
EXHIBIT 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| March 26, 2026 |
EXHIBIT 99.1 Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, CA – March 25, 2026 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc.(Nasdaq: ARTL), a clinical |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2026 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission File |
|
| March 25, 2026 |
Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 March 25, 2026 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC. 20549 Attn: Doris Stacey Gama Re: Artelo Biosciences, Inc. Registration Statement on Form S-1 (File No. 333-294579) Ladies and Gentlemen, Pursuant to Rule 461 under the Securities Act of 1933, as amended, Artelo Biosciences, Inc. he |
|
| March 24, 2026 |
As filed with the Securities and Exchange Commission on March 24, 2026 As filed with the Securities and Exchange Commission on March 24, 2026 Registration No. |
|
| March 24, 2026 |
As filed with the Securities and Exchange Commission on March 24, 2026 As filed with the Securities and Exchange Commission on March 24, 2026 Registration No. |
|
| March 24, 2026 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Artelo Biosciences, Inc. |
|
| March 24, 2026 |
EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT [], 2026 Craft Capital Management LLC 377 Oak Street, Lower Concourse Garden City, New York 11530 Attention: [CJ Hiller and Mackey McFarlane] Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Artelo Biosciences, Inc., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $[] of regis |
|
| March 24, 2026 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. EXHIBIT 4.16 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. Warrant Shares: Issue Date: [], 2026 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| March 23, 2026 |
As filed with the Securities and Exchange Commission on March 23 , 2026 As filed with the Securities and Exchange Commission on March 23 , 2026 Registration No. |
|
| March 20, 2026 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. EXHIBIT 4.15 EXHIBIT A-1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. Warrant Shares: Initial Exercise Date: , 2026 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| March 20, 2026 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. EXHIBIT 4.16 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. Warrant Shares: Issue Date: [], 2026 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| March 20, 2026 |
March 20, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, DC 20549 Attn: Doris Stacey Gama Re: Artelo Biosciences, Inc. Registration Statement on Form S-1 (File No. 333-294506) — Concurrence in Acceleration Request Ladies and Gentlemen: Craft Capital Management LLC (“Craft Capital”), solely acting as placement agent on a best-effo |
|
| March 20, 2026 |
Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 March 20, 2026 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC. 20549 Attn: Doris Stacey Gama Re: Artelo Biosciences, Inc. Registration Statement on Form S-1 (File No. 333-294506) Ladies and Gentlemen, Pursuant to Rule 461 under the Securities Act of 1933, as amended, Artelo Biosciences, Inc. he |
|
| March 20, 2026 |
As filed with the Securities and Exchange Commission on March 20, 2026 As filed with the Securities and Exchange Commission on March 20, 2026 Registration No. |
|
| March 20, 2026 |
EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT [], 2026 Craft Capital Management LLC 377 Oak Street, Lower Concourse Garden City, New York 11530 Attention: [CJ Hiller and Mackey McFarlane] Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Artelo Biosciences, Inc., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $[] of regis |
|
| March 20, 2026 |
EXHIBIT 10.30 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement” or this “SPA”) is dated as of [], 2026, between Artelo Biosciences, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co |
|
| March 20, 2026 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Artelo Biosciences, Inc. |
|
| March 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission File |
|
| March 18, 2026 |
EXHIBIT 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 12, 2026, by and between ARTELO BIOSCIENCES, INC., a Nevada corporation, with its address at 505 Lomas Santa Fe, Suite 160, Solana Beach, CA 92075 (the “Company”), and Boot Capital LLC, a Delaware limited liability company, with its address at 1688 Meridian Ave., Suite 723, Miami Beac |
|
| March 18, 2026 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 12, 2026, by and between ARTELO BIOSCIENCES, INC., a Nevada corporation, with its address at 505 Lomas Santa Fe, Suite 160, Solana Beach, CA 92075 (the “Company”), and Vanquish Funding Group Inc., a Virginia corporation, with its address at 1800 Diagonal Road, Suite 623, Alexandria, V |
|
| March 18, 2026 |
EXHIBIT 10.4 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN |
|
| March 18, 2026 |
EXHIBIT 10.3 THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN |
|
| March 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 17, 2026 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 17, 2026 |
ARTELO BIOSCIENCES, INC. INDEX TO AUDITED FINANCIAL STATEMENTS EXHIBIT 99.1 ARTELO BIOSCIENCES, INC. INDEX TO AUDITED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID 206) F-2 Consolidated Balance Sheets at December 31, 2025 and 2024 F-3 Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2025 and 2024 F-4 Consolidated Statements of Stockholders’ Equity for the years ended De |
|
| March 13, 2026 |
March 13, 2026 Gregory D. Gorga Chief Executive Officer Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 Re: Artelo Biosciences, Inc. Draft Registration Statement on Form S-1 Submitted March 09, 2026 CIK No. 0001621221 Dear Gregory D. Gorga: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registr |
|
| March 9, 2026 |
As confidentially submitted to the Securities and Exchange Commission on March 9, 2026. |
|
| March 6, 2026 |
EXHIBIT 99.1 Artelo Biosciences Announces Reverse Stock Split Shares Expected to Begin Trading on a Split-Adjusted Basis on March 10, 2026 SOLANA BEACH, CA – March 6, 2026 – Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologi |
|
| March 6, 2026 |
EXHIBIT 3.1 |
|
| March 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 5, 2026 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38951 Artelo Bioscien |
|
| February 24, 2026 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Artelo Biosciences, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock. Description of Capital Stock The following description of our capital stock is a summary and does no |
|
| February 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2026 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2026 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 5, 2026 |
EXHIBIT 10.1 EQUITY PURCHASE AGREEMENT THIS EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of January 30, 2026 (the “Execution Date”), by and between Artelo Biosciences, Inc., a corporation incorporated in the State of Nevada (the “Company”), and Square Gate Capital Master Fund, LLC- Series 5, a series limited liability company organized in the State of Delaware (the “Investor”). |
|
| February 5, 2026 |
EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January 30, 2026 (the “Execution Date”), is entered into by and between Artelo Biosciences, Inc., a corporation incorporated in the State of Nevada (the “Company”), and Square Gate Capital Master Fund, LLC- Series 5, a series limited liability company organized in the State of Delaware (togethe |
|
| February 5, 2026 |
PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK ARTELO BIOSCIENCES, INC. EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2026 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| January 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 14, 2026 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| January 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| January 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| December 11, 2025 |
ANNUAL REPORT TO SECURITY HOLDERS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38951 Artelo Bioscien |
|
| December 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State |
|
| December 1, 2025 |
December 1, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Doris Stacey Gama Re: Artelo Biosciences Inc. Registration Statement on Form S-1 File No. 333-291597 Acceleration Request Requested Date: December 2, 2025 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as |
|
| November 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commissio |
|
| November 17, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Artelo Biosciences, Inc. |
|
| November 17, 2025 |
As filed with the Securities and Exchange Commission on November 17, 2025 As filed with the Securities and Exchange Commission on November 17, 2025 Registration No. |
|
| November 17, 2025 |
EXHIBIT 3.3 Filed in the Office of Business Number E0258042011-1 FRANCISCO V. AGUILAR Secretary of State Filing Number 20255143883 401 North Carson Street Carson City, Nevada 89701-4201 Secretary of State State Of Nevada Filed On 08/29/2025 15:52:53 PM (775) 684-5708 Website: www.nvsos.gov Number of Pages 6 Profit Corporation: Certificate of Amendment (PURSUANT TO NRS 78.380 & 78.385/78.390) Certi |
|
| November 14, 2025 |
CERTIFICATE OF AMENDMENT TO BYLAWS EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO BYLAWS 1. Section 3.2 of the Bylaws is hereby amended and restated in its entirety as follows: 3.2 Vacancies. Except as otherwise provided by law, vacancies in the Board of Directors, whether caused by death, resignation, retirement, disqualification, removal, increase in the number of directors, or otherwise may be filled for the remainder of the term only |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2025 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTE |
|
| October 31, 2025 |
ARTELO BIOSCIENCES, INC. CONVERTIBLE PROMISSORY NOTE EXHIBIT 10.2 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REG |
|
| October 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 28, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| October 31, 2025 |
ARTELO BIOSCIENCES, INC. FORM OF COMMON STOCK WARRANT EXHIBIT 10.3 THIS SECURITY AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE R |
|
| October 31, 2025 |
NOTE AND WARRANT SUBSCRIPTION AGREEMENT EXHIBIT 10.1 NOTE AND WARRANT SUBSCRIPTION AGREEMENT This Note and Warrant Subscription Agreement (this “Agreement”) is entered into as of October 28, 2025 (the “Effective Date”), by and among Artelo Biosciences, Inc., a Nevada corporation (the “Company”) and the Investors listed on Schedule A hereto (the “Investors”). RECITALS A. Between April 27, 2025 and May 1, 2025, the Company entered into Su |
|
| October 27, 2025 |
ARTELO BIOSCIENCES, INC. AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT EXHIBIT 10.2 ARTELO BIOSCIENCES, INC. AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amendment to Amended and Restated Employment Agreement (the “Amendment”) is entered into and effective as of October 26, 2025 (the “Effective Date”) by and between Artelo Biosciences, Inc. (the “Company”), and Gregory D. Gorgas (“Executive”). WHEREAS, Executive previously entered into an Amended and R |
|
| October 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 26, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| October 27, 2025 |
ARTELO BIOSCIENCES, INC. EMPLOYMENT AGREEMENT EXHIBIT 10.1 ARTELO BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of October 26, 2025 by and between Artelo Biosciences, Inc. (the “Company”), and Mark Spring (“Executive”). WHEREAS, the Company and Executive desire to enter into this Agreement to provide the terms under which Executive is to be employed with the Company. WHEREAS, in consider |
|
| October 17, 2025 |
Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, California 92075 EXHIBIT 10.1 EXECUTION VERSION Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, California 92075 October 15, 2025 Daniel S. Farb Newbury St., 3rd Floor Boston, Massachusetts 02116 Ladies and Gentlemen: This letter (this “Agreement”) constitutes the agreement between (a) Artelo Biosciences, Inc. (“Company”) and (b) Daniel S. Farb and each of the other related Persons (as defined |
|
| October 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 15, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| October 1, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. Warrant Shares: [] Initial Exercise Date: September [], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| October 1, 2025 |
Artelo Biosciences Announces Proposed Underwritten Public Offering EXHIBIT 99.1 Artelo Biosciences Announces Proposed Underwritten Public Offering SOLANA BEACH, CA – September 29, 2025 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has commenced a |
|
| October 1, 2025 |
Artelo Biosciences Announces Closing of $2.0 Million Public Offering EXHIBIT 99.3 Artelo Biosciences Announces Closing of $2.0 Million Public Offering SOLANA BEACH, CA – October 1, 2025 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the closing of its |
|
| October 1, 2025 |
EXHIBIT 1.1 441,210 SHARES OF COMMON STOCK AND 13,335 PRE-FUNDED WARRANTS ARTELO BIOSCIENCES, INC. UNDERWRITING AGREEMENT September 30, 2025 R. F. Lafferty & Co., Inc. 40 Wall Street, 27th Floor New York, NY 10005 As the Representative of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, Artelo Biosciences, Inc., a company incorporated under the la |
|
| October 1, 2025 |
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering EXHIBIT 99.2 Artelo Biosciences Announces Pricing of $2.0 Million Public Offering SOLANA BEACH, CA – September 30, 2025 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc.(Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of it |
|
| October 1, 2025 |
441,210 Shares of Common Stock Pre-Funded Warrants to Purchase up to 13,335 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-273153 PROSPECTUS SUPPLEMENT (to Prospectus dated July 14, 2023) 441,210 Shares of Common Stock Pre-Funded Warrants to Purchase up to 13,335 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, Artelo Biosciences, Inc. (the “Company,” “Artelo,” “Artelo Biosciences,” “we,” “us,” and “our”) is offering up |
|
| October 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2025 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| September 30, 2025 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 30, 2025 Filed Pursuant to Rule 424(b)(5) Registration No. 333-273153 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying base prospectus are not an offer to sell and are |
|
| September 30, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-273153 PROSPECTUS SUPPLEMENT (To Prospectus dated July 14, 2023) Common Stock This prospectus supplement amends and supplements the information in the prospectus supplement, dated July 18, 2025, as supplemented by that certain prospectus supplement dated September 4, 2025 (as so supplemented, the “ATM Prospectus”), relating to the offer and sal |
|
| September 29, 2025 |
As confidentially submitted to the Securities and Exchange Commission on September 29, 2025. |
|
| September 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2025 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| September 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 9 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| September 10, 2025 |
CERTIFICATE OF AMENDMENT TO BYLAWS OF ARTELO BIOSCIENCES, INC. EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO BYLAWS OF ARTELO BIOSCIENCES, INC. 1. A new Section 9.3 is added to the Bylaws consisting of the following: In accordance with subsections 2 and 3 of NRS 78.378, the Company shall in all respects be considered an “issuing corporation” for purposes of the provisions of NRS 78.378 to 78.3793, inclusive, irrespective of whether the Company, as of any date, (i) |
|
| September 5, 2025 |
Artelo Biosciences Announces Proposed Underwritten Public Offering EXHIBIT 99.1 Artelo Biosciences Announces Proposed Underwritten Public Offering SOLANA BEACH, CA – September 3, 2025 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has commenced an |
|
| September 5, 2025 |
640,924 Shares of Common Stock Pre-Funded Warrants to Purchase up to 40,894 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-273153 PROSPECTUS SUPPLEMENT (to Prospectus dated July 14, 2023) 640,924 Shares of Common Stock Pre-Funded Warrants to Purchase up to 40,894 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, Artelo Biosciences, Inc. (the “Company,” “Artelo,” “Artelo Biosciences,” “we,” “us,” and “our”) is offering 64 |
|
| September 5, 2025 |
EXHIBIT 1.1 640,924 SHARES OF COMMON STOCK AND 40,894 PRE-FUNDED WARRANTS ARTELO BIOSCIENCES, INC. UNDERWRITING AGREEMENT September 4, 2025 R. F. Lafferty & Co., Inc. 40 Wall Street, 27th Floor New York, NY 10005 As the Representative of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, Artelo Biosciences, Inc., a company incorporated under the law |
|
| September 5, 2025 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARTELO BIOSCIENCES, INC. Warrant Shares: [] Initial Exercise Date: September [], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or af |
|
| September 5, 2025 |
Artelo Biosciences Announces Closing of $3.0 Million Public Offering EXHIBIT 99.3 Artelo Biosciences Announces Closing of $3.0 Million Public Offering SOLANA BEACH, CA – September 5, 2025 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the closing of it |
|
| September 5, 2025 |
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering EXHIBIT 99.2 Artelo Biosciences Announces Pricing of $3.0 Million Public Offering SOLANA BEACH, CA – September 4, 2025 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of it |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2025 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| September 4, 2025 |
Up to $3,451,527 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-273153 PROSPECTUS SUPPLEMENT (To Prospectus dated July 14, 2023) Up to $3,451,527 Shares of Common Stock This prospectus supplement amends and supplements the information in the prospectus supplement, dated July 18, 2025 (the “ATM Prospectus”), relating to the offer and sale of up to $6,500,000 shares of our common stock, $0.001 par value per s |
|
| September 4, 2025 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 4, 2025 Filed Pursuant to Rule 424(b)(5) Registration No. 333-273153 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying base prospectus are not an offer to sell and are |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 3, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 28, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| August 20, 2025 |
EXHIBIT 10.2 TERMINATION AGREEMENT TERMINATION AGREEMENT, dated August 19, 2025 (the “Termination Agreement”), by and between ARTELO BIOSCIENCES, INC., a Nevada corporation (the “Company”) and ABK LABS, INC., a Delaware corporation (“Consultant”). Each of the Company and Consultant are referred to in this Termination Agreement individually as a “Party” and, collectively, as the “Parties.” RECITALS |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2025 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 20, 2025 |
TERMINATION AND MUTUAL RELEASE AGREEMENT EXHIBIT 10.1 TERMINATION AND MUTUAL RELEASE AGREEMENT This Termination and Mutual Release Agreement (the “Agreement”) is entered into as of the date that the last Party executes this Agreement (the “Effective Date”), by and among ARTELO BIOSCIENCES, INC., a Nevada corporation (the “Company”), and the purchasers listed on the signature pages hereto (each, an “Investor,” and collectively, the “Inves |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BI |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State |
|
| August 7, 2025 |
Common Stock Warrant issued to ABK Labs, Inc., dated August 1, 2025 EXHIBIT 4.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH [***]. NEITHER THIS SECURITY NOR ANY SECURITIES WHICH MAY BE ISSUED UPON EXERCISE OF THIS SECURITY HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMM |
|
| August 7, 2025 |
EXHIBIT 10.1 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is entered into effective as of August 1, 2025 (the “Effective Date”) by and between Artelo Biosciences, Inc., 505 Lomas Santa Fe, Suite 160, Solana Beach, CA 92075, a Nevada Corporation (the “Company”), and ABK Labs, Inc., a Delaware corporation (“Consultant”). 1. Services. During the term of this Agreement, Consultant |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission File |
|
| August 4, 2025 |
EXHIBIT 99.1 Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression MHRA indicated ART12.11 may be a candidate for accelerated development via the Innovative Licensing and Access Pathway. SOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) - Artelo Biosciences, |
|
| August 4, 2025 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 ARTELO BIOSCIENCES, INC. (Exact name of Company as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission File |
|
| August 4, 2025 |
EXHIBIT 99.2 Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset Lead investor Bartosz Lipiński, previously Head of Engineering at Solana Labs, will serve as a technical partner CUBE selected to secure storage, staking, and active DeFi execution o |
|
| August 4, 2025 |
EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 4, 2025 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of August 1, 2025, between Artelo Biosciences, Inc., a Nevada corporation (the “Company”), and each investor identified on the signature pages hereto (each, including its successors and assigns, an “Investor” and collectively, the “Investors”). WHEREAS, subject to the terms and conditions set |
|
| August 4, 2025 |
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| July 18, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 18, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 001-38951 33-1220924 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 18, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-273153 PROSPECTUS SUPPLEMENT (to Prospectus dated July 7, 2023) $6,500,000 Common Stock This prospectus supplement relates to the issuance and sale of shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $6.50 million, from time to time solely through R.F. Lafferty & Co., Inc., as exclusive sales a |
|
| July 18, 2025 |
EXHIBIT 1.1 AT THE MARKET OFFERING AGREEMENT Up to $6,500,000 Shares of Common stock July 18, 2025 R.F. Lafferty & Co., Inc. 40 Wall Street, 29th Floor New York, NY 10005 Ladies and Gentlemen: Artelo Biosciences, Inc., a corporation organized under the laws of Nevada (the “Company”), confirms its agreement (this “Agreement”) with R.F. Lafferty & Co., Inc. (the “Manager”) as follows: 1. Definitions |
|
| July 16, 2025 |
July 16, 2025 Gregory D. Gorgas Chief Executive Officer Artelo Biosciences, Inc. 505 Lomas Santa Fe, Suite 160 Solana Beach, CA 92075 Re: Artelo Biosciences, Inc. Registration Statement on Form S-1 Filed July 11, 2025 File No. 333-288653 Dear Gregory D. Gorgas: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regardi |
|
| July 16, 2025 |
July 16, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Doris Stacey Gama Re: Artelo Biosciences Inc. Registration Statement on Form S-1 File No. 333-288653 Acceleration Request Requested Date: July 17, 2025 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as pract |
|
| July 11, 2025 |
Calculation of Filing Fee Table EXHIBIT 107 CALCULATION OF FILING FEE TABLES Form S-1 (Form Type) Artelo Biosciences, Inc. |
|
| July 11, 2025 |
ARTELO BIOSCIENCES, INC. Consolidated Balance Sheets (In thousands, except share data) EXHIBIT 99.2 Unaudited Interim Financial Statements Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024 2 Consolidated Statements of Operations for the three months ended March 31, 2025 and 2024 3 Consolidated Statements of Stockholders' Equity for the three months ended March 31, 2025 and 2024 4 Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 11, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 11, 2025 |
ARTELO BIOSCIENCES, INC. INDEX TO AUDITED FINANCIAL STATEMENTS EXHIBIT 99.1 ARTELO BIOSCIENCES, INC. INDEX TO AUDITED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID 206). 2 Consolidated Balance Sheets at December 31, 2024 and 2023. 3 Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023. 4 Consolidated Statements of Stockholders’ Equity for the years ended Decem |
|
| July 11, 2025 |
As filed with the Securities and Exchange Commission on July 11, 2025 As filed with the Securities and Exchange Commission on July 11, 2025 Registration No. |
|
| June 26, 2025 |
EXHIBIT 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 26, 2025 |
Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing EXHIBIT 99.1 Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing SOLANA BEACH, CA – June 26, 2025 – Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced it has entered into |
|
| June 26, 2025 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 24, 2025, between Artelo Biosciences, Inc., a Nevada corporation (the “Company”), and each investor identified on the signature pages hereto (each, including its successors and assigns, an “Investor” and collectively, the “Investors”). WHEREAS, subject to the terms and conditions set f |
|
| June 26, 2025 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 26, 2025 |
EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 13, 2025 |
EXHIBIT 3.1 |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 11, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 13, 2025 |
EXHIBIT 99.1 June 11, 2025 Artelo Biosciences Announces Reverse Stock Split Shares Expected to Begin Trading on a Split-Adjusted Basis on June 13, 2025 SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE) - Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid- signaling pathways to develop treatments for people living with cancer, pain, derma |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 22, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO B |
|
| May 1, 2025 |
EXHIBIT 10.3 NEITHER THIS SECURITY NOR ANY SECURITIES WHICH MAY BE ISSUED UPON EXERCISE OF THIS SECURITY HAVE BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY U.S. STATE OR OTHER JURISDICTION OR ANY EXCHANGE OR SELF-REGULATORY ORGANIZATION, IN RELIANCE UPON EXEMPTIONS FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS A |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 27, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| May 1, 2025 |
EXHIBIT 10.1 NOTE AND WARRANT SUBSCRIPTION AGREEMENT This Note and Warrant Subscription Agreement (this “Agreement”) is entered into by and between Artelo Biosciences, Inc., a Nevada corporation (the “Company”) and the Investors listed on Schedule A hereto and shall be effective as of the “Effective Date” as shown on the Company’s signature page hereto. RECITALS A. The Company’s Board of Directors |
|
| May 1, 2025 |
EXHIBIT 10.2 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REG |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 23, 2025 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| March 20, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Artelo Biosciences, Inc. |
|
| March 20, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No. |
|
| March 3, 2025 |
Insider Trading Policy, as amended EXHIBIT 19.1 ARTELO BIOSCIENCES, INC. INSIDER TRADING POLICY (Adopted on August 18, 2023) A. POLICY OVERVIEW Artelo Biosciences, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Company minimize its o |
|
| March 3, 2025 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Artelo Biosciences, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock. Description of Capital Stock The following description of our capital stock is a summary and does no |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38951 Artelo Bioscien |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 20, 2024 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissio |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTE |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38951 Artelo Bioscien |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BI |
|
| June 17, 2024 |
Artlw-form25 |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO B |
|
| March 29, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Artelo Biosciences, Inc. |
|
| March 29, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38951 Artelo Bioscien |
|
| March 25, 2024 |
EXHIBIT 97.1 ARTELO BIOSCIENCES, INC. COMPENSATION RECOVERY POLICY As adopted on November 17, 2023 Artelo Biosciences, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s pay |
|
| March 25, 2024 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Artelo Biosciences, Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock and warrants. Description of Capital Stock The following description of our capital stock is a summ |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2024 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissio |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTE |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BI |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2023 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| July 12, 2023 |
July 12, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Dillon Hagius Re: Artelo Biosciences, Inc. Registration Statement on Form S-3 Filed on July 6, 2023 File No. 333-273153 Acceleration Request Requested Date: July 14, 2023 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 |
|
| July 10, 2023 |
United States securities and exchange commission logo July 10, 2023 Gregory Gorgas President and Chief Executive Officer Artelo Biosciences, Inc. |
|
| July 7, 2023 |
July 7, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 6, 2023 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-3 (Form Type) ARTELO BIOSCIENCES, INC. |
|
| July 6, 2023 |
As filed with the Securities and Exchange Commission on July 6, 2023 As filed with the Securities and Exchange Commission on July 6, 2023 Registration No. |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2023 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State |
|
| May 16, 2023 |
!" # $ %& '( ( $) $ *+, # #$")! -. |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 or ☐ TRANSITION REPORT PERSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO B |
|
| May 11, 2023 |
Articles of Incorporation, as amended EXHIBIT 3.1 |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ Filed by the Registrant ☐ Filed by a party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 21, 2023 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| April 21, 2023 |
EXHIBIT 3.1 BYLAWS OF ARTELO BIOSCIENCES, INC. SECTION 1 SHAREHOLDERS' AND SHAREHOLDERS' MEETINGS 1.1 Annual Meeting. The annual meeting of the shareholders of Artelo Biosciences, Inc. (the "Corporation") for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at the principal office of the corporation, or at some |
|
| April 21, 2023 |
As filed with the Securities and Exchange Commission on April 21, 2023 As filed with the Securities and Exchange Commission on April 21, 2023 Registration No. |
|
| April 21, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Artelo Biosciences, Inc. |
|
| March 31, 2023 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Artelo Biosciences, Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock and warrants. Description of Capital Stock The following description of our common stock is a summa |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38951 Artelo Bioscien |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 10, 2023 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| November 8, 2022 |
EXHIBIT 21.1 Subsidiaries of Artelo Biosciences, Inc. Jurisdiction of Incorporation Artelo Biosciences Limited United Kingdom Artelo Biosciences Corporation Canada |
|
| November 8, 2022 |
EXHIBIT 3.3 BYLAWS OF ARTELO BIOSCIENCES, INC. SECTION 1 SHAREHOLDERS' AND SHAREHOLDERS' MEETINGS 1.1 Annual Meeting. The annual meeting of the shareholders of Artelo Biosciences, Inc. (the "Corporation") for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at the principal office of the corporation, or at some |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIO |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 16, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissi |
|
| August 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 24, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| August 9, 2022 |
EXHIBIT 99.1 Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy $21.3 Million in Cash and Investments as of June 30, 2022 15-for-1 Reverse Stock Split to be Effective August 10, 2022 SOLANA BEACH, Calif., Aug |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOSCIEN |
|
| August 9, 2022 |
Certificate of Change, effective August 9, 2022 EXHIBIT 3.1 |
|
| July 12, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 2, 2022 |
ARTELO BIOSCIENCES, INC. 15,000,000 Shares of common stock 424B3 1 artl424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-264967 PROSPECTUS ARTELO BIOSCIENCES, INC. 15,000,000 Shares of common stock This prospectus relates to the offer and sale from time to time of up to 15,000,000 shares of common stock, par value $0.001 per share, of Artelo Biosciences, Inc., a Nevada corporation, by Lincoln Park Capital Fund, LLC, or Lincoln Park, re |
|
| May 26, 2022 |
United States securities and exchange commission logo May 26, 2022 Gregory Gorgas Chief Executive Officer and President Artelo Biosciences, Inc. |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy Stateme |
|
| May 26, 2022 |
May 26, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance, 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Dillon Hagius Re: Artelo Biosciences, Inc. Registration Statement on Form S-1 File No. 333-264967 Acceleration Request Requested Date: May 31, 2022 Requested Time: 4:30 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securi |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy State |
|
| May 16, 2022 |
EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of May 13, 2022, is made by and between ARTELO BIOSCIENCES, INC., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the ?Buyer?). Capitalized terms used herein and not otherwise defined herein |
|
| May 16, 2022 |
Purchase Agreement between the Company and Lincoln Park Capital Fund, LLC, dated May 13, 2022. EXHIBIT 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the ?Agreement?), dated as of May 13, 2022, is made by and between ARTELO BIOSCIENCES, INC., a Nevada corporation (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof. WHEREAS: Subject to the |
|
| May 16, 2022 |
As filed with the Securities and Exchange Commission on May 16, 2022 As filed with the Securities and Exchange Commission on May 16, 2022 Registration No. |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy Statement D |
|
| May 16, 2022 |
Articles of Incorporation, as amended EXHIBIT 3.1 |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 16, 2022 |
EXHIBIT 107 Filing Fee Table Title of each class of securities to be registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share (2) Proposed maximum aggregate offering price Amount of registration fee Shares of common stock of Common Stock, par value $0. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOSCIE |
|
| April 7, 2022 |
As filed with the Securities and Exchange Commission on April 7, 2022 As filed with the Securities and Exchange Commission on April 7, 2022 Registration No. |
|
| April 7, 2022 |
EXHIBIT 107 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common Stock, $0. |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KT (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from September 1, 2021 to December 31, 2021 Commission file number 001-38951 Artel |
|
| March 21, 2022 |
EXHIBIT 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Artelo Biosciences, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), our common stock. Description of Capital Stock The following description of our common stock is a summary and does not |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 15, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 4, 2022 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 10, 2022 |
EXHIBIT 3.1 AMENDMENT TO THE BYLAWS OF ARTELO BIOSCIENCES, INC. The Bylaws (the ?Bylaws?) of Artelo Biosciences, Inc. (the ?Company?), adopted by the Board of Directors of the Company (the ?Board?) are hereby amended (the ?Amendment?) as follows: 1. The first sentence of Section 1.7 of the Bylaws is amended and restated in its entirety to read as follows: ?The presence in person or by proxy of the |
|
| February 23, 2022 |
ARTL / Artelo Biosciences Inc / Iroquois Capital Management, LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 04301G201 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 9, 2022 |
ARTL / Artelo Biosciences Inc / Parian Global Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2022 |
Joint Filing Statement Pursuant to Rule 13d-1(k)(1) CUSIP No.: 04301G201 Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, par value $0.001 per share of Artelo Biosciences, Inc. beneficially owned by them, together with any or all amendments thereto, when and if appropriate |
|
| February 4, 2022 |
ARTL / Artelo Biosciences Inc / Hudson Bay Capital Management LP - ARTL 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Artelo Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04301G201 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOS |
|
| December 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 3, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38951 Artelo Biosciences, Inc. ( |
|
| November 29, 2021 |
EXHIBIT 3.4 |
|
| November 29, 2021 |
EXHIBIT 3.5 AMENDMENT TO THE BYLAWS OF ARTELO BIOSCIENCES, INC. The Bylaws (the ?Bylaws?) of Artelo Biosciences, Inc. (the ?Company?), adopted by the Board of Directors of the Company (the ?Board?) are hereby amended (the ?Amendment?) as follows: 1. The first sentence of Section 1.7 of the Bylaws is amended and restated in its entirety to read as follows: ?The presence in person or by proxy of the |
|
| September 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 13, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commissi |
|
| July 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 22, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 16, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 15, 2021 |
EXHIBIT 3.1 AMENDMENT TO THE BYLAWS OF ARTELO BIOSCIENCES, INC. The Bylaws (the ?Bylaws?) of Artelo Biosciences, Inc. (the ?Company?), adopted by the Board of Directors of the Company (the ?Board?) are hereby amended (the ?Amendment?) as follows: 1. The first sentence of Section 1.7 of the Bylaws is amended and restated in its entirety to read as follows: ?The presence in person or by proxy of the |
|
| July 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 13, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOSCIENC |
|
| June 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy State |
|
| May 7, 2021 |
DEF 14A 1 artldef14a.htm FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6 |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: February 28, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38951 ARTELO BIOS |
|
| April 9, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-235917 PROSPECTUS SUPPLEMENT (to Prospectus dated February 3, 2020) $20,500,000 Common Stock This prospectus supplement relates to the issuance and sale of shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $20.5 million, from time to time solely through Ladenburg Thalmann & Co. Inc., as exclusiv |
|
| April 9, 2021 |
At Market Issuance Sales Agreement between the Company and Ladenburg Thalmann & Co. Inc. EXHIBIT 10.1 Artelo Biosciences, Inc. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement April 9, 2021 Ladenburg Thalmann & Co. Inc. 640 5th Avenue, 4th Floor New York, NY 10019 Ladies and Gentlemen: Artelo Biosciences, Inc., a Nevada corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Ladenburg Thalmann & Co. Inc. (the ?Agent?) as follows: 1. Issu |
|
| April 9, 2021 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement 8-K 1 artl8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of in |
|
| March 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2021 ARTELO BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada 333-199213 33-1220924 (State or other jurisdiction of incorporation) (Commission F |
|
| March 9, 2021 |
EXHIBIT 99.1 Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors LA JOLLA, Calif., March 9, 2021 - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamar |
